{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SPI-2012",
    "query": {
      "intervention": "SPI-2012"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T06:44:58.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01724866",
      "title": "Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neutropenia"
      ],
      "interventions": [
        {
          "name": "SPI-2012",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2013-03-25",
      "completion_date": "2014-08-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-15",
      "last_synced_at": "2026-09-05T06:44:58.407Z",
      "location_count": 10,
      "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Fresno, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Highland",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01724866"
    },
    {
      "nct_id": "NCT03135951",
      "title": "Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "SPI-2012",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-05-11",
      "completion_date": "2018-05-18",
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-09-05T06:44:58.407Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03135951"
    },
    {
      "nct_id": "NCT02643420",
      "title": "SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neutropenia",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "SPI-2012",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 406,
      "start_date": "2016-01-19",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-09-05T06:44:58.407Z",
      "location_count": 76,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • Yuma, Arizona + 71 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02643420"
    },
    {
      "nct_id": "NCT02953340",
      "title": "SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neutropenia",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "SPI-2012",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2017-05-10",
      "completion_date": "2019-05-06",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-09-05T06:44:58.407Z",
      "location_count": 49,
      "location_summary": "Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953340"
    },
    {
      "nct_id": "NCT04570423",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Eflapegrastim",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-05-20",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-05T06:44:58.407Z",
      "location_count": 5,
      "location_summary": "Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04570423"
    }
  ]
}